The Office of Health Economics (OHE) have published a consulting report discussing the use of a cost-per-QALY gained decision rule to appraise treatments for very rare conditions. The report has been published as part of the NICE Highly Specialised Technologies (HST) programme and argues that it is inappropriate to focus a HST appraisal on only a cost-per-QALY measure and that the thresholds recommended seem arbitrary.
A health economist, Professor Philip Clarke on behalf of the Mt Hood Diabetes Challenge Network, has compiled a list of health economics journals indicating the open access fee (in US dollars) and impact factor scores, alongside a link to the journals website with information on how to submit a paper.
The Health Economics Research Centre (HERC) at the Nuffield Department of Population Health, University of Oxford, have published their February 2018 newsletter. The newsletter features articles on the cost-effectiveness of bowel screening kits in England, the cost of blood transfusion, the impact of chronic kidney disease on household income and EU-funded project on Alzheimer’s Disease. There is also a spotlight feature on Frauke Becker and updates on staffing, events, publications and presentations.
The Health Economics Research Centre at the Nuffield Department of Population Health, University of Oxford, have updated their database of studies that map to EQ-5D from other patient-reported outcome measures or clinical instruments. The database presents details of the sample size, modelling methods and patient population, in addition to the citation details and source instruments that are mapped in each of the studies meeting the inclusion criteria. Also, an article summarising the methods of the literature review and the results has been published in the journal Health and Quality of Life Outcomes.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) have released their list of the top ten influential topics in health economics and outcomes research for 2018. The full list is: 1. Drug pricing and spending; 2. Innovative and curative therapies; 3. Accelerated drug approvals; 4. Universal health coverage; 5. Aging population; 6. mHealth; 7. Diagnostics; 8. Biosimilars; 9. Preventive medicine; 10. Disruptive innovators. Further details on each topic are available in the report.
The Academic Health Economists’ Blog has a short blog post on Q methodology as its ‘Method of the Month’ feature. The piece is written by Helen Mason of Glasgow Caledonian University.
The Winter newsletter from Health Economics at Bristol (HEB) has been published. Alongside updates on staffing and publications, the newsletter features recent funding from the Horizon 2020 program for a project to establish standardised costing and outcome assessment measures across the European Union, research on the cost-effectiveness of shortened treatment duration for chronic hepatitis C virus and staff involvement in a consultation on the financial and moral complexities of NHS prescriptions for gluten free goods. The newsletter also highlights the Summer Meeting of HESG which is to be held at Bristol in June 2018. The period for abstracts submission opened on 1st February.